Efficacy and Safety of Chemotherapy or <scp>EGFR</scp> ‐ <scp>TKIs</scp> as First‐Line Therapy in <scp>NSCLC</scp> Patients Harboring Non‐Ex 20 Ins Uncommon <scp>EGFR</scp> Mutations: A Retrospective Study in China
Taking into account both efficacy and safety, afatinib and osimertinib are better choices than chemotherapy and first-generation EGFR-TKIs for NSCLC patients with non-ex 20 ins uncommon EGFR mutations. L861Q showed a trend toward a better response to afatinib, while in those without L861Q and G719X mutations, osimertinib might be a better choice. Safety also should be a concern when choosing EGFR-TKI for treatment, patients should pay attention to the management of safety when using afatinib while osimertinib is safer.
Authors
- Yong He (ORCID: https://orcid.org/0000-0002-9404-798X)
- Shipeng Lei
- Qingle Liang (ORCID: https://orcid.org/0009-0008-5975-2078)
- Defeng Hu
- Yubo Wang (ORCID: https://orcid.org/0000-0002-1019-5388)
- Tingting He (ORCID: https://orcid.org/0000-0001-7523-6550)
- Chen Liao
- Li Bai (ORCID: https://orcid.org/0000-0002-6283-986X)
Institutions
- Army Medical University (CN)
- Chongqing University (CN)
- Daping Hospital (CN)
- Xinqiao Hospital (CN)
- Jiangjin Central Hospital (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1002/cam4.70542
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.42